|
|
|
| Effects of Sanqi Panaxnotoginseng Injection combined with Gliclazide and Melbine for diabetic nephropathy |
| DENG Tingting HUANG Xiangyang |
| The Fourth Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Liuzhou 545005, China |
|
|
|
|
Abstract [Abstract] Objective To discuss the clinical therapy effect and safety degree of type Ⅱ diabetic nephropathy by the intervention treatment of Sanqi Panaxnotoginseng Injection combined with Gliclazide and Melbine. Methods From September 2011 to December 2014, in Department of Endocrinology, the Fourth Affiliated Hospital of Guangxi Medical University, 80 patients with diabetic nephropathy (DN) were selected as research subjects, all of them belonged to the newest diagnosis standard of WHO of type Ⅱ diabetes patients and they were divided into observation group and control group according to random number table, with 40 patients in each group. The patients of two groups were educated with basic knowledge of diabetes before medical treatment, patients in control group were treated with Gliclazide sustained-release tablets by oral administration, 60 mg/time, 3 times/d and metformin hydrochloride enteric coated tablets by oral administration, 0.5 g/time, 3 times/d; patients in observation group were treated with injection of Sanqi Panaxnotoginseng Injection as supplement, 10 mL/time, twice/d. The therapy period involved three weeks. Before and after the therapy, all of the blood flow indexes, coagulation indexes, excretion of urinary protein and adverse reaction were recorded. Results After the therapy, patients in observation group had significant improvements in low shear blood viscosity, plasma viscosity and red cell assembling index, the differences were statistically significant (P < 0.05); the coagulation indexes of patients in observation group recovered to within the range of reference value and displayed great improvement compared with that of control group, the differences were statistically significant (P < 0.05); the urinary albumin excretion rate of patients in observation group were lower compared with that of control group, the differences were statistically significant (P < 0.05), while the testing result of serum creatinine of two groups, the differences was not statistically significant (P > 0.05). During the three-week therapy period patients from both groups showed no adverse effect. Conclusion There is good therapy effect and high safety degree of intervention treating type Ⅱ diabetic nephropathy with Sanqi Panaxnotoginseng Injection, which deserves further development.
|
|
|
|
|
|
[参考文献]
[1] 夏国新，梁锋.2型糖尿病患者血小板功能及活化分子标志物测定[J].微循环学杂志，2010，（1）：64.
[2] 邹永红，张永明，撒小军，等.糖尿病肾病发生时蛋白质、脂质代谢变化的临床观察及意义[J].中国医药科学，2013， 3（11）：175-176.
[3] 王伟川.氯沙坦的降压效应和肾脏饱和作用研究[J].中国医药科学，2013，3（12）：73-74.
[4] 王蕾，贾振祥，戴巍，等.硫辛酸注射液治疗老年早期糖尿病肾病临床分析[J].河北医药，2013，35（4）：553-554.
[5] 傅彬.前列地尔与缬沙坦联合用药治疗早期糖尿病肾病的临床研究[J].贵阳中医学院学报，2013，35（3）：69-70.
[6] 刘海青.缬沙坦联合硝苯地平控释片治疗老年高血压合并2型糖尿病肾病的疗效观察[J].河北医药，2013，35（4）：554-555.
[7] 施赛珠，陈剑秋，张茂华，等.糖尿病血瘀证血检前状态分子标志物关系的研究[J].中医研究，1996，9（2）：21-22.
[8] 刘恩.厄贝沙坦联合丹参治疗2型糖尿病肾病蛋白尿的临床效果分析[J].中国医药指南，2013，11（2）：192-193.
[9] 吴栋良，宫计划，陈燕，等.复方丹参滴丸联合厄贝沙坦对老年早期2型糖尿病肾病患者尿微量白蛋白影响的研究[J].河北医学，2015，21（3）：428-431.
[10] 田领，刘景峰，勾艳丽，等.通心络胶囊联合厄贝沙坦对早期糖尿病肾病患者肾功能及内皮功能的影响[J].疑难病杂志，2015，14（6）：615-617，625.
[11] 王燕.早期糖尿病肾病患者血浆D-二聚体、纤维蛋白原、同型半胱氨酸的表达及其临床意义[J].中国医药导报，2015，12（9）：81-84.
[12] 田爱荣.糖尿病肾病中医证候研究紧进展[J].中医临床研究，2013，5（12）：116-117.
[13] 陈际芳，赵兰坤，苏卫东.三七总皂苷注射液与复方丹参注射液治疗冠心病心绞痛的比较[J].中国新药与临床杂志，2000，19（6）：459.
[11] 简道林.三七总皂苷对完全性脑缺血损伤复苏效应的实验研究[J].中华麻醉学杂志，1993，13（4）：261.
[12] 李明初，廖长琦，谢守勇.复方血栓通对早、中期糖尿病肾病患者ACR、肝功能及血脂代谢的影响[J].中国实验方剂学杂志，2014，20（19）：178-181.
[13] 张桢.复方血栓通胶囊治疗早期糖尿病肾病的临床研究[J].国际中医中药杂志，2014，36（7）：610-612.
[14] 张桢.复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响[J].中国医药指南，2013，11（34）：13-14.
[15] 杨萍，孙书明，魏祎.血栓通与贝那普利对早期糖尿病肾病炎症因子的影响[J].天津医药，2014，42（7）：716-718. |
|
|
|
